Mapi Pharma’s long-acting formulation of glatiramer acetate, GA Depot, may help stabilize disability scores over time in people with both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). That’s according to new analyses of data from an open-label Phase 2a clinical trial (NCT03362294) in PPMS and a pivotal Phase 3 clinical trial […]
The post AAN 2026: GA Depot may help stabilize disability in RMS and PPMS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com